辉瑞2025年第四季度营收175.6亿美元，非新冠业务增长9%，26全年营收指引595-625亿美元｜财报见闻

Core Insights - Pfizer demonstrated robust operational resilience during its strategic transformation phase, with total revenue reaching $62.6 billion in 2025, reflecting a 6% growth in core business excluding COVID-related products [1][4] - The company maintained its 2026 performance guidance while revealing an active product pipeline, expecting to initiate approximately 20 key clinical trials in 2026, laying the foundation for long-term growth [1][4] Financial Performance - Total revenue for Q4 2025 was $17.6 billion, a 1% decrease from Q4 2024, while full-year revenue decreased by 2% to $62.6 billion [2] - Adjusted diluted EPS for Q4 was $0.66, a 5% increase year-over-year, and for the full year, it reached $3.22, up 4% [2][3] - The adjusted sales cost ratio improved to 24.2%, down from 25.8% in 2024, indicating enhanced cost management [8] Business Segments - Non-COVID product lines showed strong structural growth, with cardiovascular and vaccine segments leading the way; Eliquis generated $8 billion in revenue, a growth of 8% [4][5] - The oncology business achieved $16.8 billion in revenue, an 8% increase, with key products like Ibrance and Xtandi maintaining strong market positions despite competition [6] - COVID-related product revenues significantly declined, with Comirnaty and Paxlovid generating $4.4 billion and $2.4 billion respectively, down 18% and 59% year-over-year [7] Strategic Initiatives - Pfizer completed the acquisition of Metsera for approximately $7 billion, marking its entry into the obesity and metabolic disease treatment market [9] - The company is advancing its obesity pipeline, with promising results from the clinical trials of its long-acting GLP-1 receptor agonist [10] - Multiple oncology products received regulatory breakthroughs, enhancing the competitive edge of Pfizer's oncology portfolio [11][12] 2026 Outlook - Pfizer projects 2026 revenue between $59.5 billion and $62.5 billion, including approximately $5 billion from COVID-related products [13] - The company plans to maintain a focus on reducing debt levels and balancing its capital structure, with no share buybacks planned for 2026 [13]